Popular Show Features Company's Technology Platform
WORCESTER — Advanced Cell Technology, Inc. (OTCBB: ACTC – News), a biotechnology company applying cellular technology in the field of regenerative medicine, announced that company Chairman and Chief Executive Officer William M. Caldwell IV was interviewed yesterday on Bloomberg Radio's popular mid-day program, The Hays Advantage, hosted by Kathleen Hays.
The discussion covered Advanced Cell's retinal pigment epithelium (RPE) cell program for the treatment of Stargardt's disease and age-related macular degeneration (AMD), which is the leading cause of blindness in Americans over 60 years of age. Mr. Caldwell and Mr. Hays discussed the size of the potential market for an embryonic stem cell-based cure for AMD, with Mr. Caldwell commenting, "Kathleen, if you and I live long enough, we most likely will get [AMD]. Over ten million Americans suffer from this disease.”
Mr. Caldwell was Ms. Hays' sole guest for the wide-ranging, 20-minute interview. Other topics included health care reform, the importance of government funding of basic science research and development, and the investment potential of Advanced Cell Technology and other companies working in the regenerative medicine field.
Ms. Hays concluded the discussion of AMD and the potential for ACTC's RPE therapy to address the disease with a positive assessment: "It seems that, as a society, we might come out ahead, investing all the money in companies like yours, paying for these treatments, if [the result is that people suffering from AMD] can still see when they get old.”
Mr. Caldwell also discussed some of Advanced Cell Technology's other research programs, including its research into producing blood from embryonic stem cells, saying, "We can manufacture blood, and hopefully that will have all sorts of applications, including for the military… to address issues around the lack of blood for soldiers out in the field.” He also discussed the company's Myoblast program for the treatment of heart failure.
Mr. Caldwell commented on the overall stem cell industry, saying, "It's an exciting field and it needs a little bit of a kick-start. That's why we believe our initial indication will help validate the industry, because it's what we believe to be low-hanging fruit.”
Click here to download an audio file of the interview
The Company also announced that it would present today at BIO- Europe Spring 2010 4th Annual International Partnering Conference, an event that brings many of the leading international biotechnology companies to Barcelona, Spain.